News und Analysen
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma reports sustained growth in 2021
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject
Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021
Regulatory News:
AD HOC-MITTEILUNG GEMÄSS ART. 53 KR
Die Vifor Pharma Gruppe verzeichnete 2021 eine solide Geschäftsentwicklung und eine Steigerung der Profitabilität, die von einer starken
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt
Vifor Pharma Deutschland GmbH hat heute die Markteinführung von Tavneos® bekannt gegeben, der ersten in Europa zugelassenen oralen Therapie für die Behandlung der beiden Haupttypen von
Vifor Pharma appoints two new members to the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005992/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
CSL Limited announces tender offer to acquire Vifor Pharma Ltd
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Global biotechnology leader CSL Limited (ASX: CSL; USOTC:CSLLY) and Vifor Pharma Ltd (SIX:VIFN; ISIN:CH0364749348), a global
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
First patient enrolled in phase-IIa study of vamifeport in patients with sickle cell disease
Vifor Pharma today announced that the first patient has been enrolled in a double-blind, randomized phase-IIa clinical trial evaluating the safety, efficacy and tolerability of vamifeport in adult
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of Hervé Gisserot as Chief Commercial Officer and member of the Vifor Pharma
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
Vifor Pharma announces changes to the Executive Committee as CFO retires
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer will retire from the company by the end of December 2021
Invitation: Straumann Group 2022 first-quarter sales webcast
Einladung: Straumann Group Webcast - Umsatzzahlen 1. Quartal 2022
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
DGAP-News: BB Biotech AG concludes its share buyback program and launches a new buyback program
Straumann Group Aktionärinnen und Aktionäre wählen Nadia Tarolli Schmidt als neues Mitglied des Verwaltungsrates und genehmigen alle weiteren Anträge
Straumann Group shareholders elect Nadia Tarolli Schmidt as a new Board member and approve all further proposals
Straumann Group ernennt neue Geschäftsleitungsmitglieder, um Wachstumsstrategie weiter voranzutreiben
Straumann Group announces new Executive Management Board members to support growth strategy